“Background/Aim”: the current inability to diagnose Pancreatic Cancer Adenocarcinoma (PDAC) at an early stage strongly influences therapeutic strategies. Protein Induced by Vitamin K Absence (PIVKA II) showed an accurate diagnostic performance for PDAC. Since circulating PIVKA II has been recently associated with pancreatic origin cells with Vimentin, an epithelial-to-mesenchymal transition (EMT) early activation marker, the aim of this study was to investigate in vivo the combination between the two proteins. “Materials and Methods”: we assayed the presence of PIVKA II and Vimentin proteins by using different diagnostic methods. A total of 20 PDAC patients and 10 healthy donors were tested by Western Blot analysis; 74 PDAC patient and 46 healthy donors were assayed by ECLIA and Elisa. “Results”: Western Blot analysis showed the concomitant expression of PIVKA II and Vimentin in PDAC patient sera. Immunometric assay performed on a larger cohort of patients demonstrated that 72% of PIVKA II-positive PDAC patients were Vimentin-positive. Additionally, in a group of PDAC patients with PIVKA II levels ≥2070 ng/mL, the percentage of Vimentin-positive subjects reached 84%. “Conclusion“: the association between PIVKA II protein and the EMT suggests that this molecule could be considered a marker of the acquisition of an aggressive phenotype.
“背景/目的”：目前无法在早期阶段诊断胰腺导管腺癌（PDAC）极大地影响了治疗策略。维生素K缺乏诱导蛋白（PIVKA II）对PDAC显示出良好的诊断性能。鉴于循环PIVKA II近期被发现与表达波形蛋白（Vimentin）的胰腺来源细胞相关，而波形蛋白是上皮-间质转化（EMT）的早期激活标志物，本研究旨在体内探讨这两种蛋白的联合表达情况。“材料与方法”：我们采用不同检测方法分析PIVKA II与波形蛋白的表达水平。通过蛋白质印迹法检测20例PDAC患者与10例健康供体；采用电化学发光免疫分析法与酶联免疫吸附法检测74例PDAC患者及46例健康供体。“结果”：蛋白质印迹分析显示PDAC患者血清中同时存在PIVKA II与波形蛋白表达。大样本免疫检测表明，72%的PIVKA II阳性PDAC患者同时呈现波形蛋白阳性。值得注意的是，在PIVKA II水平≥2070 ng/mL的PDAC患者亚组中，波形蛋白阳性比例高达84%。“结论”：PIVKA II蛋白与EMT进程的关联性提示，该分子可被视为侵袭性表型获得的潜在标志物。
肿瘤(癌症)患者之家